- Home
- DSGX vs LEGN Comparison
DSGX vs LEGN Comparison
Compare DSGX & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DSGX | LEGN |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.9B |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DSGX | LEGN |
|---|---|---|
| Price | $69.44 | $17.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | ★ $107.13 | $63.08 |
| AVG Volume (30 Days) | 531.4K | ★ 1.1M |
| Earning Date | 03-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.37 | $43.65 |
| Revenue Next Year | N/A | $32.75 |
| P/E Ratio | $37.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $62.56 | $16.24 |
| 52 Week High | $117.35 | $45.30 |
Technical Indicators
Market Signals| Indicator | DSGX | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.76 | 46.14 |
| Support Level | $68.82 | $17.46 |
| Resistance Level | $74.91 | $20.39 |
| Average True Range (ATR) | 2.34 | 0.75 |
| MACD | -0.07 | 0.11 |
| Stochastic Oscillator | 13.78 | 40.98 |
Price Performance
Historical ComparisonAbout DSGX Descartes Systems Group Inc. (The)
Descartes Systems Group provides a software solution that allows users in the shipping industry to communicate with one another. Its core product is the Global Logistics Network, which is best understood as transaction-driven. Descartes charges clients to send/receive messages, data, and documents on the GLN. Customers typically contract for a monthly minimum over a multiyear period. The GLN platform allows Descartes to upsell additional software modules as well, typically provided via a software-as-a-service model.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.